Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer

BJU International

Volumn 110, Issue 8, 2012, Pages 1169-1176

  Van Rhijn, Bas W G ^a,b,d,f   Liu, Liyang ^b   Vis, André N ^d   Bostrom, Peter J ^a   Zuiverloon, Tahlita C M ^d,e   Fleshner, Neil E ^a   Van Der Aa, Madelon N M ^d   Alkhateeb, Sultan S ^a   Bangma, Chris H ^d   Jewett, Michael A S ^a   Zwarthoff, Ellen C ^e   Bapat, Bharati ^b   Van Der Kwast, Theo H ^c,e   Zlotta, Alexandre R ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

bladder; cancer; EORTC; sub stage; T1; TNM

Indexed keywords

BCG VACCINE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN P27; PROTEIN P53; CYCLINE; P27 ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; EUROPEAN ORGANISATION FOR THE RESEARCH AND TREATMENT OF CANCER RISK SCORE; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; SEX DIFFERENCE; UNIVERSITY HOSPITAL; BLADDER TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; MUTATION; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84871882021     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.10996.x     Document Type: Article

References (30)

1. Sobin DH, Wittekind CH, eds. TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002: 199-202
2. Nieder AM, Brausi M, Lamm D, et al,. Management of stage T1 tumors of the bladder: international consensus panel. Urology 2005; 66: 108-25
3. van Rhijn BW, Burger M, Lotan Y, et al,. Recurrence and Progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56: 430-42
4. Stein JP, Penson DF,. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 2008; 102: 270-5
5. Sylvester RJ, van der Meijden AP, Lamm DL,. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70
6. Babjuk M, Oosterlinck W, Sylvester R, et al,. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
7. Herr HW,. Is maintenance Bacillus Calmette-Guérin really necessary? Eur Urol 2008; 54: 971-3
8. Griffiths TR, Charlton M, Neal DE, Powell PH,. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002; 167: 2408-12
9. Younes M, Sussman J, True LD,. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990; 66: 543-8
10. Hermann GG, Horn T, Steven K,. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998; 159: 91-4
11. Shariat SF, Weizer AZ, Green A, et al,. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 2000; 56: 735-40
12. Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand H, Bittard H,. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol 2001; 165: 42-6
13. Orsola A, Trias I, Raventos CX, et al,. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-Non-treated patients. Eur Urol 2005; 48: 231-8
14. Mhawech-Fauceglia P, Fischer G, Alvarez V Jr, Ahmed A, Herrmann FR,. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int 2007; 100: 1182-7
15. Eble J, Sauter G, Epstein J, Sesterhenn I,. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004
16. van der Aa MN, van Leenders GJ, Steyerberg EW, et al,. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 2005; 36: 981-6
17. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al,. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-77
18. van Rhijn BW, Zuiverloon TCM, Vis AN, et al,. Molecular Grade (FGFR3/MIB-1) and EORTC risk-scores are predictive in primary non-muscle invasive bladder cancer. Eur Urol 2010; 58: 433-41
19. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y,. P53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000; 38: 691-9
20. van Rhijn BW, Vis AN, van der Kwast TH, et al,. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003; 21: 1912-21
21. Shariat SF, Bolenz C, Godoy G, et al,. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009; 182: 78-84
22. Billerey C, Chopin DK, Aubriot-Lorton MH, et al,. Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors. Am J Pathol 2001; 158: 1955-9
23. Hernandez S, Lopez-Knowles E, Lloreta J, et al,. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 2005; 11: 5444-50
24. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE,. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 2007; 99: 281-5
25. van Oers JM, Lurkin I, van Exsel AJ, et al,. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005; 11: 7743-8
26. Mungan NA, Aben KK, Schoenberg MP, et al,. Gender differences in stage-adjusted bladder cancer survival. Urology 2000; 55: 876-80
27. Horstmann M, Witthuhn R, Falk M, Stenzl A,. Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med 2008; 5: 385-94
28. Saint F, Patard JJ, Maille P, et al,. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002; 167: 364-7
29. Herr HW, Donat SM, Dalbagni G,. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 2007; 177: 75-9
30. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F,. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010; 58: 185-90